Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04048018
Other study ID # B2694-CTPR
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 5, 2019
Est. completion date June 30, 2021

Study information

Verified date July 2021
Source BioMérieux
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection. This study is designed to assess (1) the sensitivity of this assay, (2) its percent agreement with other diagnostic tests, (3) its measurement precision , and (4) any potential interference of the presence of other non-tuberculosis mycobacterial bacterial infections with this assay.


Description:

Tuberculosis (TB) infection is one of the top 10 causes of death in the world and the leading cause of death due to a single infectious agent. Millions of people are infected with TB each year which can pose significant economic and health care burdens on the global population. TB can infected the lungs (pulmonary TB) or other organs such as the brain, and kidneys (extra-pulmonary TB). When a person with pulmonary TB coughs or sneezes, water droplets containing M. tuberculosis are expelled into the air. Persons can become infected with TB when they inhale air containing these water droplets, however, not everyone infected with Mycobacterium tuberculosis (Mtb) becomes ill. Therefore two TB-related conditions exist: latent TB infection (LTBI) and TB disease. People with latent TB infection are not ill and do not present TB symptoms or have TB disease. The only sign of TB infection is a positive reaction to the tuberculin skin test or TB blood tests such as IGRA tests. People with latent TB infection are not contagious and cannot spread TB infection to others. Identification and treatment of LTBI can substantially reduce the risk of developing active disease. However, there is no diagnostic gold standard for LTBI. Two types of test are currently available for the identification of LTBI: the tuberculin skin test (TST) and the TB Interferon Gamma (IFN-γ) Release Assay (TB-IGRA). Evidence suggests that both TST and TB-IGRA are acceptable but not perfect because they detect indirect markers of Mtb exposure and indicate a cellular immune response to M. tuberculosis. TB-IGRAs have a number of advantages compared to TST which promote their progressive adoption in the clinical practice and in guidelines.


Recruitment information / eligibility

Status Completed
Enrollment 2401
Est. completion date June 30, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 2 Years and older
Eligibility Active TB Population Inclusion Criteria: A person classified as or suspected of having M. tuberculosis disease (active TB): A person with known HIV status, determined by a laboratory or rapid test performed no earlier than one month prior to, or at the time of inclusion into this study A person of age = 2 years Exclusion Criteria: A person who has been on an anti-TB treatment for >15 days for the ongoing infection Pregnant women A person who has received an anti-tumor necrosis factor (TNF) alpha treatment within the previous 3 months A person who has had prior TST A person with an NTM infection A person with positive HIV status. High Risk for TB infection Inclusion criteria : A person who is at increased risk for M. tuberculosis infection (and therefore LTBI) and/or for progression to active TB: A person with age = 2 years A person with known HIV status Non-inclusion criteria will be: A person who has or has had active TB A person who has received treatment for active TB or LTBI A person who has received an anti-TNF alpha treatment A person who has had a TST Pregnant women Person who has been an NTM infection Low Risk for TB Infection Inclusion criteria Generally healthy people, unlikely to have encountered TB disease in the past, that may be subject to TB testing for professional, academic or personal reasons (e.g.: students, healthcare personnel and healthcare volunteers, military recruits) A person with age = 18 years old Non-inclusion criteria A person who is considered at high risk for LTBI A person who has or has had active TB A person who has received treatment for active TB or LTBI A person who has received an anti-TNFalpha treatment A person who has had a TST Pregnant women A person who has been diagnosed with a NTM infection NTM population: Inclusion criteria A person who is positive for NTM of interest confirmed by culture and identification; Non-inclusion criteria A person who has been on antibiotic treatment for NTM; A person with confirmed active TB; A person with HIV; A person with a history of active TB; A person who have received treatment for LTBI; A person who is at high risk for LTBI Pregnant women. Precision Population Inclusion criteria: A person previously enrolled in the Active TB, High Risk or Low Risk studies, or a blood donor. Non-inclusion criteria An adult who was not previously enrolled in the Active TB, High Risk or Low Risk studies except for blood donors For blood donors only: A person who can be classified as being at increased risk for M. tuberculosis infection (and therefore LTBI) and/or for progression to active TB

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Blood draw and IGRA test
One to two blood samples will be obtained from participants in all arms in order to conduct testing.

Locations

Country Name City State
Brazil Universidade Federal de Mato Grosso do Sul (UFMS) Campo Grande
Brazil Universidade Federal Da Grande Dourados (UFGD) Dourados
France Anti-TB center of Chambéry Chambéry
France Lapeyronie Hospital Montpellier
France Anti-TB center of Nanterre Nanterre Cedex
France Avicenne Hospital Paris
France Lariboisière Hospital Paris
France North Hospital Saint-Étienne
Georgia National Center for Tuberculosis and Lung Disease Tbilisi
India Hinduja Hospital Mumbai
Italy INMI L. Spallanzani Rome
Mexico Autonomous University of Baja California Mexicali
South Africa TASK Applied Science, Delft Day Hospital Premises Cape Town
South Africa University of Cape Town Centre for Lung Infection and Immunity South Africa
United Kingdom Evelina London Children's Hospital London
United Kingdom Royal Free Hospital London
United Kingdom St Thomas' Hospital London
United States University of Illinois- Chicago Chicago Illinois
United States Naional Jewish Health Denver Colorado
United States University of Florida Gainesville Florida
United States Rutgers University Newark New Jersey
United States Stanford University Palo Alto California
United States Saint Louis University Saint Louis Missouri
United States UC San Diego San Diego California

Sponsors (1)

Lead Sponsor Collaborator
BioMérieux

Countries where clinical trial is conducted

United States,  Brazil,  France,  Georgia,  India,  Italy,  Mexico,  South Africa,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Positive, negative, indeterminate for tuberculosis The VIDAS or comparator assays will qualitatively determine the presence or absence of Mycobacterial TB infection in a participant's blood. This measurement is based on the level of interferon gamma released after stimulation of T cells in blood. One-time measurement through study completion for each participant, an average of 5 months.
Primary Sensitivity and positive and negative percent agreement for the VIDAS TB IGRA assay with comparator assay Results obtained using the VIDAS assay will be compared with the results obtained from other methods. One-time measurement through study completion for each participant, an average of 5 months.
Primary Degree of Interference by nontuberculous mycobacteria for the VIDAS TB IGRA assay Persons with NTM will be tested using the VIDAS TB IGRA. One-time measurement through study completion for each participant, an average of 5 months.
Primary Measurement Precision of the VIDAS TB IGRA assay results 6- 4mL blood samples will be collected from each participant and tested using different VIDAS instruments. Triplicate measurement per sample through study completion, an average of 5 months.
See also
  Status Clinical Trial Phase
Completed NCT04094012 - Risk of SDRs Under 3HP and 1HP Regimen for LTBI Phase 3
Completed NCT01582711 - Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT Phase 3
Recruiting NCT06033807 - Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
Completed NCT01622140 - Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
Completed NCT00557765 - Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area N/A
Completed NCT00463086 - Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons N/A
Active, not recruiting NCT01398618 - Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI) Phase 3
Recruiting NCT00905970 - Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection N/A
Recruiting NCT00449345 - Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis N/A
Completed NCT02641106 - VDOT for Monitoring Adherence to LTBI Treatment N/A
Completed NCT00804713 - Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits N/A
Completed NCT01136161 - Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection Phase 2
Recruiting NCT03312647 - Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection N/A
Completed NCT02810678 - Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment N/A
Completed NCT01223534 - QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study. Phase 4
Withdrawn NCT00558480 - Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis N/A
Recruiting NCT00692809 - Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection N/A
Completed NCT03702049 - Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV N/A
Terminated NCT01761201 - "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". Phase 3
Completed NCT01608685 - Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients N/A